The Impact of Nocturnal Hypoglycemia on Clinical and Cost-Related Issues in Patients With Type 1 and Type 2 Diabetes

The Diabetes Educator

Volumn 40, Issue 3, 2014, Pages 269-279

  Edelman, Steven V ^a   Blose, Jamie S ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Center for Integrated Drug Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT;

ANALYSIS; BLOOD; COMPLICATION; COST OF ILLNESS; ECONOMICS; GLUCOSE BLOOD LEVEL; HEALTH CARE COST; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; SELF CARE; SLEEP DISORDER;

BLOOD GLUCOSE; CHRONOBIOLOGY DISORDERS; COST OF ILLNESS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HEALTH CARE COSTS; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; SELF-MANAGEMENT;

EID: 84908689468     PISSN: 01457217     EISSN: 15546063     Source Type: Journal    
DOI: 10.1177/0145721714529608     Document Type: Article

References (58)

1. Allen KV, Frier BM. Nocturnal hypoglycemia: clinical manifestations and therapeutic strategies toward prevention. Endocr Pract. 2003;9:530-543.
2. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
3. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.
4. American Diabetes Association. Standards of medical care in diabetes—2012. Diabetes Care. 2012;35(suppl 1):S11-S63.
5. Garber AJ, Abrahamson MJ, Barzilay JI et al. AACE comprehensive diabetes management algorithm 2013. Endocr Pract. 2013;19:327-336.
6. The DCCT Research Group. Epidemiology of severe hypoglycemia in the diabetes control and complications trial. Am J Med. 1991;90:450-459.
7. Lipska KJ, Warton EM, Huang ES et al. HbA1c and risk of severe hypoglycemia in type 2 diabetes: the Diabetes and Aging Study. Diabetes Care. 2013;36:3535-3542.
8. Seaquist ER, Anderson J, Childs B et al. Hypoglycemia and diabetes: a report of a workgroup of the american diabetes association and the endocrine society. Diabetes Care. 2013;36:1384-1395.
9. Gabriely I, Shamoon H. Hypoglycemia in diabetes: common, often unrecognized. Cleve Clin J Med. 2004;71:335-342.
10. Bay C, Kristensen PL, Pedersen-Bjergaard U, Tarnow L, Thorsteinsson B. Nocturnal continuous glucose monitoring: accuracy and reliability of hypoglycemia detection in patients with type 1 diabetes at high risk of severe hypoglycemia. Diabetes Technol Ther. 2013;15:371-377.
11. Zijlstra E, Heise T, Nosek L, Heinemann L, Heckermann S. Continuous glucose monitoring: quality of hypoglycaemia detection. Diabetes Obes Metab. 2013;15:130-135.
12. Lerman IG, Wolfsdorf JI. Relationship of nocturnal hypoglycemia to daytime glycemia in IDDM. Diabetes Care. 1988;11:636-642.
13. Chico A, Vidal-Rios P, Subira M, Novials A. The continuous glucose monitoring system is useful for detecting unrecognized hypoglycemias in patients with type 1 and type 2 diabetes but is not better than frequent capillary glucose measurements for improving metabolic control. Diabetes Care. 2003;26:1153-1157.
14. Munshi MN, Segal AR, Suhl E et al. Frequent hypoglycemia among elderly patients with poor glycemic control. Arch Intern Med. 2011;171:362-364.
15. Signorovitch JE, Macaulay D, Diener M et al. Hypoglycaemia and accident risk in people with type 2 diabetes mellitus treated with non-insulin antidiabetes drugs. Diabetes Obes Metab. 2012;15:335-341.
16. Tattersall RB, Gill GV. Unexplained deaths of type 1 diabetic patients. Diabet Med. 1991;8:49-58.
17. Weston PJ, Gill GV. Is undetected autonomic dysfunction responsible for sudden death in type 1 diabetes mellitus? The “dead in bed” syndrome revisited. Diabet Med. 1999;16:626-631.
18. Tanenberg RJ, Newton CA, Drake AJ. Confirmation of hypoglycemia in the “dead-in-bed” syndrome, as captured by a retrospective continuous glucose monitoring system. Endocr Pract. 2010;16:244-248.
19. Gill GV, Woodward A, Casson IF, Weston PJ. Cardiac arrhythmia and nocturnal hypoglycaemia in type 1 diabetes—the “dead in bed” syndrome revisited. Diabetologia. 2009;52:42-45.
20. Bell D. What is the cause of “dead in bed” syndrome? Available at: http://www.healio.com/endocrinology/news/print/endocrine-today/%7BB072CD05-C4C8-45BE-B7BC-F711FD8A162B%7D/What-is-the-cause-of-dead-in-bed-syndrome. Accessed August 31, 2012.
21. Parekh B. The mechanism of dead-in-bed syndrome and other sudden unexplained nocturnal deaths. Curr Diabetes Rev. 2009;5:210-215.
22. Cryer PE. Glucose counterregulatory hormones: physiology, pathophysiology, and relevance to clinical hypoglycemia. Available at: http://www.msdlatinamerica.com/diabetes/sid340838.html. Accessed November 30, 2012.
23. Cryer PE. Hypoglycemia-associated autonomic failure in diabetes. Am J Physiol Endocrinol Metab. 2001;281:E1115-E1121.
24. Cryer PE. The barrier of hypoglycemia in diabetes. Diabetes. 2008;57:3169-3176.
25. Brisoce SA, Davis SN. Hypoglycemia in type 1 and type 2 diabetes: physiology, pathophysiology, and managment. Clin Diabetes. 2006;24:115-121.
26. de Galan BE, Schouwenberg BJ, Tack CJ, Smits P. Pathophysiology and management of recurrent hypoglycaemia and hypoglycaemia unawareness in diabetes. Neth J Med. 2006;64:269-279.
27. Banarer S, Cryer PE. Sleep-related hypoglycemia-associated autonomic failure in type 1 diabetes: reduced awakening from sleep during hypoglycemia. Diabetes. 2003;52:1195-1203.
28. Young A. Inhibition of glucagon secretion. Adv Pharmacol. 2005;52:151-171.
29. Unger RH, Cherrington AD. Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover. J Clin Invest. 2012;122:4-12.
30. Segel SA, Paramore DS, Cryer PE. Hypoglycemia-associated autonomic failure in advanced type 2 diabetes. Diabetes. 2002;51:724-733.
31. Veneman T, Mitrakou A, Mokan M, Cryer P, Gerich J. Induction of hypoglycemia unawareness by asymptomatic nocturnal hypoglycemia. Diabetes. 1993;42:1233-1237.
32. Brunton SA. Nocturnal hypoglycemia: answering the challenge with long-acting insulin analogs. MedGenMed. 2007;9:38.
33. Cryer P, Childs B. Negotiating the barrier of hypoglycemia in diabetes. Diabetes Spectrum. 2002;15:20-27.
34. Cox DJ, Irvine A, Gonder-Frederick L, Nowacek G, Butterfield J. Fear of hypoglycemia: quantification, validation, and utilization. Diabetes Care. 1987;10:617-621.
35. Fidler C, Elmelund CT, Gillard S. Hypoglycemia: an overview of fear of hypoglycemia, quality-of-life, and impact on costs. J Med Econ. 2011;14:646-655.
36. Lawton J, Rankin D, Elliott J et al. Experiences, views, and support needs of family members of people with hypoglycemia unawareness: interview study. Diabetes Care. 2014;37:109-115.
37. Wild D, von MR, Brohan E, Christensen T, Clauson P, Gonder-Frederick L. A critical review of the literature on fear of hypoglycemia in diabetes: implications for diabetes management and patient education. Patient Educ Couns. 2007;68:10-15.
38. Polonsky WH, Davis CL, Jacobson AM, Anderson BJ. Correlates of hypoglycemic fear in type I and type II diabetes mellitus. Health Psychol. 1992;11:199-202.
39. Sheu WH, Ji LN, Nitiyanant W et al. Hypoglycemia is associated with increased worry and lower quality of life among patients with type 2 diabetes treated with oral antihyperglycemic agents in the Asia-Pacific region. Diabetes Res Clin Pract. 2012;96:141-148.
40. Leiter L, Yale J, Chiasson J, Harris S, Kleinstiver P, Sauriol L. Assessment of the impact of fear of hypoglycemic episodes on glycemic and hypoglycemia management. Canadian Journal of Diabetes. 2005;29:186-192.
41. Marrett E, Radican L, Davies MJ, Zhang Q. Assessment of severity and frequency of self-reported hypoglycemia on quality of life in patients with type 2 diabetes treated with oral antihyperglycemic agents: a survey study. BMC Res Notes. 2011;4:251.
42. King P, Kong MF, Parkin H, Macdonald IA, Tattersall RB. Well-being, cerebral function, and physical fatigue after nocturnal hypoglycemia in IDDM. Diabetes Care. 1998;21:341-345.
43. Fanelli CG, Paramore DS, Hershey T et al. Impact of nocturnal hypoglycemia on hypoglycemic cognitive dysfunction in type 1 diabetes. Diabetes. 1998;47:1920-1927.
44. Davis RE, Morrissey M, Peters JR, Wittrup-Jensen K, Kennedy-Martin T, Currie CJ. Impact of hypoglycaemia on quality of life and productivity in type 1 and type 2 diabetes. Curr Med Res Opin. 2005;21:1477-1483.
45. Bohme P, Bertin E, Cosson E, Chevalier N. Fear of hypoglycaemia in patients with type 1 diabetes: do patients and diabetologists feel the same way? Diabetes Metab. 2012;39:63-70.
46. Ratner RE, Gough SCL, Mathieu C et al. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials. Diabetes Obes Metab. 2013;15:175-184.
47. Kovacs BK, Nicolucci A, Holt RI et al. Diabetes Attitudes, Wishes and Needs second study (DAWN2): cross-national benchmarking indicators for family members living with people with diabetes. Diabet Med. 2013;30:778-788.
48. Williams SA, Shi L, Brenneman SK, Johnson JC, Wegner JC, Fonseca V. The burden of hypoglycemia on healthcare utilization, costs, and quality of life among type 2 diabetes mellitus patients. J Diabetes Complications. 2012;26:399-406.
49. Zhang Y, Wieffer H, Modha R. The burden of hypoglycemia in type 2 diabetes: a systematic review of patient and economic perspectives. JCOM. 2010;17:547-557.
50. Harris S, Leiter L, Yale J, Chiasson J, Kleinstiver P, Souriol L. Out-of-pocket costs of managing hyperglycemia and hypoglycemia in patients with type 1 diabetes and insulin-treated type 2 diabetes. Can J Diabetes. 2007;31:25-33.
51. Brod M, Christensen T, Bushnell DM. Impact of nocturnal hypoglycemic events on diabetes management, sleep quality, and next-day function: results from a four-country survey. J Med Econ. 2012;15:77-86.
52. Brod M, Christensen T, Thomsen TL, Bushnell DM. The impact of non-severe hypoglycemic events on work productivity and diabetes management. Value Health. 2011;14:665-671.
53. Brod M, Wolden M, Christensen T, Bushnell DM. A nine country study of the burden of non-severe nocturnal hypoglycemic events on diabetes management and daily function. Diabetes Obes Metab. 2013;25:546-557.
54. Barnett AH, Cradock S, Fisher M, Hall G, Hughes E, Middleton A. Key considerations around the risks and consequences of hypoglycaemia in people with type 2 diabetes. Int J Clin Pract. 2010;64:1121-1129.
55. Ismail-Beigi F, Moghissi E, Tiktin M, Hirsch IB, Inzucchi SE, Genuth S. Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials. Ann Intern Med. 2011;154:554-559.
56. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Prolonged nocturnal hypoglycemia is common during 12 months of continuous glucose monitoring in children and adults with type 1 diabetes. Diabetes Care. 2010;33:1004-1008.
57. Woodward A, Weston P, Casson IF, Gill GV. Nocturnal hypoglycaemia in type 1 diabetes—frequency and predictive factors. QJM. 2009;102:603-607.
58. Valla V. Therapeutics of diabetes mellitus: focus on insulin analogues and insulin pumps. Exp Diabetes Res. 2010;2010: 178372.